Microhealth GTM brain

category

market profile

• text: Rare bleeding disorder care relies on patient-reported treatment events and clinician follow-up between visits.
• text: The network can support pharmaceutical evidence generation as well as patient and provider workflows.

personas

• title: Hemophilia treatment center clinician
  pains:

  • Limited visibility into bleeds and treatments between visits
  • Manual follow-up across patients with complex regimens
• title: Patient or caregiver managing a bleeding disorder
  pains:

  • Tracking treatments, symptoms and sharing progress with care teams
  • Managing a lifelong condition outside the clinic
• title: Pharmaceutical real-world evidence lead
  pains:

  • Finding longitudinal patient-reported outcomes in rare diseases
  • Understanding unmet needs and real-world treatment patterns

icp

• text: Hemophilia treatment centers and hematology teams serving rare bleeding disorders or sickle cell disease.
• text: Pharmaceutical companies with rare hematology therapies and a need for patient-reported evidence.

message pillars

• text: Connect clinical teams to patients between appointments.
• text: Turn patient treatment data into evidence for research.
• text: Give patients control over data sharing.

objections

• objection: Patients may be reluctant to share sensitive health information.
  response: Explain patient control over sharing, explicit consent for research and the stated security safeguards.
• objection: A rare disease dataset may be too small to inform decisions.
  response: Discuss network coverage, cohort suitability and data quality for the specific research question.

competitors

• name: Takeda myPKFiT
  why: Hemophilia tracking and individualized treatment management.
• name: Pfizer HemMobile
  why: Patient app for hemophilia treatment and bleed tracking.

keywords

• hemophilia treatment tracking app
• bleeding disorder patient reported outcomes
• hemophilia real world evidence
• sickle cell care management
• hemophilia treatment center dashboard
• rare disease patient monitoring

voice

• Supportive and patient-centered
• Clinical and evidence-oriented
• Reassuring about privacy

signals

• text: A treatment center wants more visibility into treatment and bleeds between patient visits.
• text: A pharmaceutical team is planning evidence generation for a rare blood disorder therapy.

pricing

motion

channels

• provider partnerships
• pharmaceutical partnerships
• patient communities
• app stores

confidence

Founders

• name: Miguel Lara
  title: Founder/CEO
  role: CEO
  bio: ● 15+ years as digital health startup CEO ● Deep relationships across the biopharma ecosystem ● 10+ years as Managing Director (healthcare) at global bank ● Y Combinator (YC_S15) alumni
• name: Marc Lara
  title: Founder
  role: Founder
  bio: Expert indigital health, including: - Launching products for new therapeutic areas - Improving health outcomes - Clinical and HEOR studies - Domestic and global deployments - Predictive AI for medical and commercial goals